InvestorsHub Logo
Followers 27
Posts 2742
Boards Moderated 0
Alias Born 03/17/2017

Re: None

Wednesday, 10/23/2019 8:27:14 AM

Wednesday, October 23, 2019 8:27:14 AM

Post# of 232695
In comparison, CLSD licensed XIPERA pre-approval for 20% on sales today, i.e. ~2.5% below 50% profits using average margin & costs.

This is considered a great deal actually (o8>

But they got an CRL plus additional data request + FDA meeting (so no clean slate Class-1 review). They aim resubmission complete in 1Q20.

XIPERA and its injector is eye care related only, modest revenue.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News